<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00045786</url>
  </required_header>
  <id_info>
    <org_study_id>CC-1088-MDS-801-001</org_study_id>
    <nct_id>NCT00045786</nct_id>
  </id_info>
  <brief_title>Study to Determine the Safety and Preliminary Efficacy of CC-1088 in the Treatment of Myelodysplastic Syndromes</brief_title>
  <official_title>A Multi-center, An Open Label, Dose-Escalation Study to Determine the Safety and Preliminary Efficacy of CC-1088 in the Treatment for Myelodysplastic Syndromes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celgene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Celgene</source>
  <brief_summary>
    <textblock>
      The primary objective of the study is to assess the safety of CC-1088 to patients with&#xD;
      myelodysplastic syndromes (MDS).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2001</start_date>
  <completion_date type="Actual">November 2003</completion_date>
  <primary_completion_date type="Actual">December 2001</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Myelodysplastic Syndrome</condition>
  <arm_group>
    <arm_group_label>400 mg CC-1088</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>800 mg CC-1088</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>1200 mg CC-1088</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>1500 mg CC-1088</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CC-1088</intervention_name>
    <description>400 mg/day (200 mg orally twice a day) 800 mg/day (400 mg orally twice a day) 1200 mg/day (600 mg orally twice a day) 1500 mg/day (500 mg orally three times daily)</description>
    <arm_group_label>1200 mg CC-1088</arm_group_label>
    <arm_group_label>1500 mg CC-1088</arm_group_label>
    <arm_group_label>400 mg CC-1088</arm_group_label>
    <arm_group_label>800 mg CC-1088</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Eligible patients must have a diagnosis of MDS of at least 12 weeks that is not&#xD;
             therapy related.&#xD;
&#xD;
          -  Age â‰¥ 18 at the time of signing informed consent&#xD;
&#xD;
          -  Patient must be able to adhere to the study visit schedule and other protocol&#xD;
             requirements.&#xD;
&#xD;
          -  Patient must understand and voluntarily sign an informed consent document.&#xD;
&#xD;
          -  Women of childbearing potential (WCBP) must have a negative serum or urine pregnancy&#xD;
             test.&#xD;
&#xD;
          -  Sexually active WCBP must agree to use adequate contraceptive methods (oral,&#xD;
             injectable, or implantable hormonal contraceptive; tubal ligation; intra-uterine&#xD;
             device; barrier contraceptive with spermicide; or vasectomized partner).&#xD;
&#xD;
          -  Women must not be pregnant or lactating.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Pregnant and lactating women and WCBP who are not using adequate contraception.&#xD;
&#xD;
          -  Myelosclerosis (or myelofibrosis) occupying &gt;30% of marrow space&#xD;
&#xD;
          -  Patients with iron deficiency (e.g., absent bone marrow iron store). If a marrow&#xD;
             aspirate is not evaluable for storage iron, transferrin saturation must be 220% and&#xD;
             serum femtin not less than 50 ng/mL.&#xD;
&#xD;
          -  Patients with uncorrected Bl2 or folate deficiency.&#xD;
&#xD;
          -  Patients with contributing causes of anemia such as autoimmune or heredity, hemolytic&#xD;
             disorders, or GI blood loss.&#xD;
&#xD;
          -  Patients with a history of malignancy, except basal cell or squamous cell carcinoma of&#xD;
             the skin or cervical carcinoma in situ.&#xD;
&#xD;
          -  Patients with clinically significant, symptomatic and unstable pulmonary,&#xD;
             cardiovascular, endocrine, neurologic, gastrointestinal or genitourinary system&#xD;
             diseases unrelated to their underlying hematologic disorder.&#xD;
&#xD;
          -  Life-threatening or active infection requiring parenteral antibiotic therapy or other&#xD;
             serious concurrent illness.&#xD;
&#xD;
          -  Patients who have a history of testing positive for Hepatitis B surface&#xD;
             antigenemia,'Hepatitis C, or HIV.&#xD;
&#xD;
          -  Inadequate organ hction: renal insufficiency [serum creatinine levels &gt;1.5 x upper&#xD;
             limit of normal (ULN)] or hepatic impairment (bilirubin 22 mg/dL or AST/ALT 22 x ULN).&#xD;
&#xD;
          -  Patients may not have received another investigational study drug within 30 days of&#xD;
             entry in the present study.&#xD;
&#xD;
          -  Requirement for ongoing therapy with corticosteroids.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Knight</last_name>
    <role>Study Director</role>
    <affiliation>Celgene Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rush-Presbyterian-St Luke's Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612-3515</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <study_first_submitted>September 9, 2002</study_first_submitted>
  <study_first_submitted_qc>September 10, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 11, 2002</study_first_posted>
  <last_update_submitted>April 24, 2017</last_update_submitted>
  <last_update_submitted_qc>April 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>myelodysplastic syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

